
  
    
      
        Background_NNP
        Glucocorticoids_NNP influence_NN a_DT wide_JJ spectrum_NN of_IN cellular_JJ
        functions_NNS through_IN their_PRP$ action_NN on_IN soluble_JJ intracellular_NN
        receptors_NNS ._. In_IN most_JJS cells_NNS ,_, unliganded_JJ glucocorticoid_NN
        receptors_NNS (_( GR_NNP )_) reside_VB predominately_RB in_IN the_DT cytoplasm_NN ,_, where_WRB
        they_PRP exist_VBP as_IN a_DT heteromeric_JJ complex_JJ comprised_VBN minimally_RB of_IN
        GR_NNP ,_, 90_CD -_: kDa_NN and_CC 70_CD -_: kDa_NN heat_NN shock_NN proteins_NNS (_( hsp_NN 90_CD and_CC
        hsp_NN 70_CD )_) ._. Other_JJ proteins_NNS (_( i_NNP ._. e_SYM ._. p_NN 60_CD /_NN Hop_NNP ,_, p_NN 23_CD ,_, hsp_NN 40_CD ,_, FKBP_NNP 52_CD ,_,
        and_CC FKBP_NNP 51_CD )_) have_VBP been_VBN implicated_VBN in_IN the_DT
        assembly_NN /_NN stabilization_NN of_IN the_DT GR-hsp_NNP 90_CD -_: hsp_NN 70_CD -_: complex_JJ in_IN a_DT
        form_NN that_WDT has_VBZ high_JJ affinity_NN for_IN agonist_NN [_NN for_IN review_NN ,_, see_VB
        Ref_NNP ._. 1_LS ,_, 2_CD ,_, 3_CD ]_NN ._. Upon_IN agonist_NN binding_VBG ,_, the_DT complex_JJ undergoes_NNS
        a_DT transformation_NN ,_, and_CC the_DT ligand_NN bound_VBN GR_NNP translocates_NNS into_IN
        to_TO the_DT nucleus_NN in_IN a_DT manner_NN that_WDT is_VBZ determined_VBN by_IN a_DT nuclear_JJ
        localization_NN sequence_NN (_( NLS_NNP )_) contained_VBD in_IN the_DT receptor_NN [_NN 4_CD ]_NN ._.
        There_EX the_DT GR_NNP acts_NNS as_IN a_DT ligand-activated_JJ transcriptional_NN
        stimulator_NN or_CC repressor_NN of_IN primary_JJ response_NN genes_NNS by_IN
        binding_JJ to_TO glucocorticoid_NN hormone-responsive_JJ elements_NNS (_( GRE_NNP )_)
        contained_VBD in_IN the_DT promoter_NN regions_NNS of_IN steroid-responsive_JJ
        genes_NNS and_CC either_CC facilitating_VBG or_CC repressing_VBG the_DT formation_NN
        of_IN an_DT active_JJ transcriptional_NN complex_JJ ._.
        Although_IN little_JJ is_VBZ known_VBN about_IN the_DT molecular_JJ machinery_NN
        that_WDT regulates_VBZ steroid_NN receptor_NN movement_NN through_IN the_DT
        cytoplasm_NN and_CC into_IN the_DT nucleus_NN ,_, several_JJ studies_NNS suggest_VBP
        that_DT movement_NN is_VBZ influenced_VBN by_IN reversible_JJ phosphorylation_NN ._.
        Evidence_NN for_IN this_DT originated_VBN from_IN the_DT studies_NNS of_IN Qi_NNP et_CC al_NN ._.
        [_NN 5_CD ,_, 6_CD ]_NN ,_, which_WDT revealed_VBD that_IN the_DT hormone_NN insensitivity_NN
        produced_VBN by_IN cellular_JJ transformation_NN with_IN v-mos_JJ (_( a_DT
        serine_NN /_NN threonine_NN protein_NN kinase_NN that_IN acts_NNS as_IN an_DT oncogene_NN )_)
        results_NNS from_IN both_DT a_DT decrease_NN in_IN the_DT nuclear_JJ retention_NN of_IN
        liganded_JJ receptor_NN and_CC a_DT decrease_NN in_IN the_DT reutilization_NN of_IN GR_NNP
        protein_NN that_IN cycles_NNS back_RB into_IN the_DT cytoplasm_NN ._. Subsequently_RB ,_,
        DeFranco_NNP et_CC al_NN ._. [_NN 7_CD ]_NN reported_VBD that_DT treatment_NN with_IN okadaic_JJ
        acid_NN ,_, a_DT potent_JJ ser_NN /_NN thr_NN protein_NN phosphatase_NN inhibitor_NN ,_, also_RB
        results_VBZ in_IN inefficient_JJ nuclear_JJ retention_NN of_IN agonist-bound_JJ
        GR_NNP and_CC the_DT cytoplasmic_JJ "_'' trapping_VBG "_'' of_IN GR_NNP in_IN a_DT form_NN that_WDT is_VBZ
        unable_JJ to_TO "_'' recycle_VB "_'' ._. Recent_JJ studies_NNS with_IN okadaic_JJ acid_NN
        suggest_VBP phosphorylation_NN alters_NNS the_DT high_JJ affinity_NN binding_JJ of_IN
        GR_NNP to_TO hsp-_NN 90_CD ,_, and_CC that_IN an_DT intact_JJ cytoskeleton_NN is_VBZ required_VBN
        for_IN ligand-activated_JJ GR_NNP translocation_NN through_IN the_DT cytoplasm_NN
        to_TO the_DT nucleus_NN [_NN 8_CD ]_NN ._.
        The_DT ability_NN of_IN okadaic_JJ acid_NN to_TO influence_VB the_DT
        intracellular_NN partitioning_VBG of_IN GR_NNP suggests_VBZ that_IN an_DT okadaic_JJ
        acid_NN sensitive_JJ ser_NN /_NN thr_NN protein_NN phosphatase_NN (_( PPase_NNP )_)
        participates_VBZ in_IN the_DT regulation_NN of_IN GR_NNP movement_NN ._. In_IN vitro_NN ,_,
        okadaic_JJ acid_NN acts_NNS as_IN a_DT potent_JJ inhibitor_NN of_IN serine_NN /_NN threonine_NN
        protein_NN phosphatases_NNS type_NN 1_CD (_( PP_NNP 1_LS )_) and_CC 2_CD A_DT (_( PP_NNP 2_CD A_DT )_) [_NN 9_CD ,_, 10_CD ]_NN ._.
        Accordingly_RB ,_, many_JJ of_IN the_DT effects_NNS produced_VBN by_IN the_DT treatment_NN
        of_IN cells_NNS with_IN okadaic_JJ acid_NN have_VBP been_VBN attributed_VBN to_TO the_DT
        inhibition_NN of_IN these_DT two_CD enzymes_NNS ._. However_RB ,_, due_JJ to_TO toxicity_NN
        and_CC solubility_NN constraints_NNS ,_, in_IN living_VBG cells_NNS it_PRP is_VBZ difficult_JJ
        to_TO distinguish_VB the_DT actions_NNS of_IN PP_NNP 2_CD A_DT from_IN those_DT of_IN PP_NNP 1_CD using_VBG
        okadaic_JJ acid_NN ._. Furthermore_RB ,_, in_IN humans_NNS ,_, it_PRP is_VBZ now_RB clear_JJ that_IN
        there_EX are_VBP four_CD isoforms_NNS of_IN PP_NNP 1_CD [_NN PP_NNP 1_CD α_NN ,_, PP_NNP 1_CD δ_NN ,_, PP_NNP 1_CD γ_NN 
        1_CD and_CC PP_NNP 1_CD γ_NN 
        2_CD [_NN 11_CD ,_, 12_CD ,_, 13_CD ]_NN ,_, two_CD isoforms_NNS of_IN PP_NNP 2_CD A_DT
        (_( PP_NNP 2_CD A_DT α_NN and_CC PP_NNP 2_CD Aβ_NNP [_NN 14_CD ,_, 15_CD ]_NN )_) and_CC four_CD structurally_RB related_VBN
        phosphatases_NNS ,_, PP_NNP 4_CD [_NN 16_CD ]_NN ,_, PP_NNP 5_CD [_NN 17_CD ,_, 18_CD ]_NN ,_, PP_NNP 6_CD [_NN 19_CD ]_NN and_CC PP_NNP 7_CD [_NN
        20_CD ]_NN ._. Although_IN detailed_JJ dose-response_JJ studies_NNS have_VBP not_RB been_VBN
        reported_VBN for_IN native_JJ PP_NNP 5_CD ,_, PP_NNP 6_CD and_CC PP_NNP 7_CD ,_, studies_NNS with_IN PP_NNP 4_CD [_NN
        21_CD ]_NN and_CC recombinant_JJ PP_NNP 5_CD [_NN 18_CD ]_NN indicate_VBP they_PRP are_VBP also_RB
        sensitive_JJ to_TO okadaic_JJ acid_NN ._. Like_IN calcineurin_NN (_( PP_NNP 2_CD B_NNP )_) and_CC
        PP_NNP 2_CD C_NNP ,_, PP_NNP 7_CD is_VBZ apparently_RB insensitive_JJ to_TO inhibition_NN by_IN
        okadaic_JJ acid_NN [_NN 20_CD ]_NN ._.
        Recent_JJ studies_NNS indicate_VBP that_IN PP_NNP 5_CD associates_NNS with_IN the_DT
        GR-hsp_NNP 90_CD complex_JJ [_NN 22_CD ,_, 23_CD ]_NN suggesting_VBG that_IN PP_NNP 5_CD may_MD
        influence_VB the_DT actions_NNS of_IN GRs_NNP ._. However_RB ,_, studying_VBG the_DT
        cellular_JJ roles_NNS of_IN PP_NNP 5_CD has_VBZ proven_VBN difficult_JJ ,_, in_IN part_NN ,_,
        because_IN no_DT physiological_JJ substrates_NNS for_IN PP_NNP 5_CD have_VBP been_VBN
        identified_VBN ._. In_IN addition_NN ,_, in_IN crude_NN cell_NN homogenates_NNS PP_NNP 5_CD
        resides_VBZ predominately_RB in_IN an_DT inactive_JJ state_NN that_WDT represents_VBZ
        <_NN 1_CD %_NN of_IN the_DT measurable_JJ PPase_NNP activity_NN ._. To_TO characterize_VB
        the_DT cellular_JJ roles_NNS of_IN PP_NNP 5_CD we_PRP have_VBP ,_, therefore_RB ,_, developed_VBD
        chimeric_JJ antisense_NN 2_CD '_POS -_: 
        O_NNP -_: (_( 2_CD -_: methoxy_NN )_) ethylphosphothioate_NN
        oligonucleotides_NNS capable_JJ of_IN inhibiting_VBG the_DT expression_NN of_IN
        human_JJ PP_NNP 5_CD at_IN nanomolar_NN concentrations_NNS ._. Because_IN the_DT lead_JJ
        compound_NN targeting_VBG PP_NNP 5_CD (_( ISIS_NNP 15534_CD )_) acts_NNS via_IN RNAase_NNP H_NNP
        mediated_JJ degradation_NN ,_, studies_NNS with_IN ISIS_NNP 15534_CD do_VBP not_RB allow_VB
        us_PRP to_TO assess_VB how_WRB rapid_JJ changes_NNS in_IN PP_NNP 5_CD activity_NN affect_NN
        cellular_JJ functions_NNS (_( Northern_NNP analysis_NN indicate_VBP that_IN it_PRP
        takes_VBZ ~_NN 6_CD for_IN the_DT mRNA_NN degradation_NN to_TO occur_VB and_CC ,_, due_JJ to_TO the_DT
        half-life_NN of_IN the_DT preexisting_VBG protein_NN ,_, it_PRP takes_VBZ ~_NN 24_CD hours_NNS
        for_IN the_DT protein_NN levels_NNS to_TO fall_VB [_NN 24_CD ]_NN ._. Nonetheless_RB ,_, ISIS_NNP
        15534_CD potently_RB inhibits_NNS the_DT expression_NN of_IN PP_NNP 5_CD in_IN cultured_JJ
        cells_NNS for_IN ~_NN 48_CD -_: 72_CD hours_NNS (_( IC_NNP 
        50_CD of_IN <_NN 75_CD nm_NN )_) ,_, which_WDT affords_NNS a_DT ~_NN
        24_CD -_: 48_CD hour_NN window_NN in_IN which_WDT the_DT expression_NN of_IN PP_NNP 5_CD is_VBZ
        essentially_RB ablated_JJ [_NN 24_CD ,_, 25_CD ]_NN ._. More_RBR importantly_RB ,_, because_IN
        ISIS_NNP 15534_CD has_VBZ no_DT effect_NN on_IN the_DT structurally_RB related_VBN PPases_NNP
        [_NN 24_CD ]_NN ,_, it_PRP can_MD be_VB employed_VBN to_TO specifically_RB inhibit_VB the_DT
        actions_NNS of_IN PP_NNP 5_CD by_IN suppressing_VBG PP_NNP 5_CD protein_NN levels_NNS in_IN
        cultured_JJ human_JJ cells_NNS ._.
        To_TO assess_VB the_DT role_NN of_IN PP_NNP 5_CD in_IN the_DT regulation_NN of_IN
        GR-mediated_NNP events_NNS ,_, binding_JJ studies_NNS were_VBD conducted_VBN with_IN [_NN
        3_CD H_NNP ]_NN dexamethasone_NN before_IN and_CC after_IN ISIS_NNP 15534_CD -_: mediated_JJ
        suppression_NN of_IN PP_NNP 5_CD expression_NN ._. These_DT studies_NNS revealed_VBD that_IN
        the_DT suppression_NN of_IN PP_NNP 5_CD expression_NN had_VBD no_DT apparent_JJ effect_NN on_IN
        dexamethasone_NN binding_JJ ,_, suggesting_VBG that_IN PP_NNP 5_CD does_VBZ not_RB affect_VB
        the_DT formation_NN of_IN the_DT high-affinity_JJ ligand_NN binding_JJ complex_NN
        or_CC hormone_NN binding_VBG to_TO the_DT GR_NNP [_NN 25_CD ]_NN ._. In_IN contrast_NN ,_, mobility_NN
        gel-shift_JJ analysis_NN revealed_VBD that_DT treatment_NN with_IN ISIS_NNP 15534_CD
        produces_VBZ a_DT marked_VBN increase_NN in_IN the_DT association_NN of_IN GR_NNP with_IN
        GRE-containing_NNP DNA_NNP ,_, and_CC transient_JJ transfection_NN studies_NNS
        employing_VBG a_DT GR-responsive_NNP reporter_NN plasmid_NN revealed_VBD that_IN
        the_DT suppression_NN of_IN PP_NNP 5_CD expression_NN activates_NNS GR-dependent_NNP
        transcription_NN in_IN the_DT absence_NN of_IN hormone_NN [_NN 25_CD ]_NN ._. When_WRB A_DT 549_CD
        cells_NNS were_VBD treated_VBN with_IN ISIS_NNP 15534_CD and_CC then_RB dexamethasone_NN ,_,
        the_DT effect_NN was_VBD additive_JJ ,_, with_IN maximal_NN dexamethasone_NN induced_VBD
        luciferase_NN activity_NN ~_NN 10_CD times_NNS greater_JJR than_IN the_DT maximal_NN
        dexamethasone-induced_JJ response_NN attainable_JJ in_IN the_DT presence_NN
        of_IN PP_NNP 5_CD [_NN 25_CD ]_NN ._. Together_RB ,_, these_DT studies_NNS indicate_VBP that_IN PP_NNP 5_CD
        acts_NNS as_IN a_DT suppressor_NN of_IN GR-induced_NNP transcription_NN ._.
        To_TO further_VB characterize_VB the_DT mechanism_NN by_IN which_WDT PP_NNP 5_CD
        affects_VBZ GR_NNP function_NN ,_, in_IN the_DT present_JJ study_NN we_PRP employed_VBN a_DT
        GR-GFP_NNP fusion_NN protein_NN and_CC fluorescent_NN microscopy_NN to_TO follow_VB
        the_DT movement_NN of_IN GR_NNP in_IN cells_NNS treated_VBN with_IN dexamethasone_NN and_CC
        ISIS_NNP 15534_CD ._. These_DT studies_NNS indicate_VBP that_IN PP_NNP 5_CD mediated_JJ
        suppression_NN of_IN GR-function_NNP arises_VBZ from_IN the_DT ability_NN of_IN PP_NNP 5_CD
        to_TO suppress_VB the_DT nuclear_JJ accumulation_NN of_IN GRs_NNP ._.
      
      
        Results_NNS
        
          Inhibition_NNP of_IN PP_NNP 5_CD by_IN okadaic_JJ acid_NN
          Okadaic_NNP acid_NN is_VBZ widely_RB employed_VBN to_TO inhibit_VB PPase_NNP
          activity_NN in_IN eukaryotic_JJ cells_NNS ,_, and_CC the_DT observed_VBD effects_NNS
          are_VBP often_RB attributed_VBN to_TO the_DT inhibition_NN of_IN PP_NNP 1_CD and_CC PP_NNP 2_CD A_DT ._.
          However_RB ,_, as_IN seen_VBN in_IN Figure_NN 1_CD ,_, the_DT dephosphorylation_NN of_IN
          phosphohistone_NN by_IN the_DT catalytic_JJ subunit_NN of_IN purified_JJ PP_NNP 5_CD
          from_IN bovine_JJ brain_NN is_VBZ also_RB potently_RB inhibited_VBD by_IN okadaic_JJ
          acid_NN ._. Okadaic_NNP acid_NN inhibits_NNS the_DT activity_NN of_IN PP_NNP 5_CD in_IN a_DT
          dose-dependent_JJ manner_NN ,_, having_VBG an_DT IC_NNP 
          50_CD of_IN 5_CD ._. 58_CD +_NN /_NN -_: 0_CD ._. 41_CD nM_NN ._. Under_IN
          identical_JJ assay_NN conditions_NNS ,_, okadaic_JJ acid_NN is_VBZ a_DT more_RBR potent_JJ
          inhibitor_NN of_IN PP_NNP 2_CD A_DT (_( IC_NNP 
          50_CD ~_NN 0_CD ._. 05_CD nM_NN )_) and_CC weaker_JJR inhibitor_NN of_IN
          PP_NNP 1_CD (_( IC_NNP 
          50_CD ~_NN 45_CD nM_NN )_) ._. However_RB ,_, the_DT activity_NN of_IN
          PP_NNP 5_CD against_IN histone_NN (_( 865_CD +_NN /_NN -_: 31_CD nMoles_NNS Pi_NNP /_NN min_NN /_NN mg_NN protein_NN )_)
          is_VBZ less_JJR than_IN that_DT of_IN PP_NNP 2_CD A_DT ._. Therefore_RB ,_, whereas_IN assays_NNS
          conducted_VBN with_IN PP_NNP 1_CD and_CC PP_NNP 2_CD A_DT were_VBD conducted_VBN with_IN a_DT
          concentration_NN of_IN enzyme_NN that_WDT is_VBZ diluted_VBN below_IN the_DT
          titration_NN endpoint_NN (_( defined_VBN as_IN the_DT concentration_NN of_IN
          enzyme_NN after_IN which_WDT further_JJ dilution_NN no_RB longer_RB affects_VBZ the_DT
          IC_NNP 
          50_CD ;_: [_NN 26_CD ]_NN )_) because_IN the_DT activity_NN of_IN
          PP_NNP 5_CD upon_IN further_JJ dilution_NN was_VBD below_IN that_DT necessary_JJ for_IN
          accurate_JJ quantification_NN ,_, we_PRP could_MD not_RB establish_VB a_DT clear_JJ
          titration_NN endpoint_NN with_IN PP_NNP 5_CD ._. Based_VBN on_IN titration_NN studies_NNS
          with_IN microcystin-_NN LR_NNP to_TO estimate_VB the_DT actual_JJ amount_NN of_IN PP_NNP 5_CD
          in_IN the_DT reaction_NN ,_, an_DT estimate_NN of_IN the_DT K_NNP 
          i_NNP for_IN okadaic_JJ acid_NN is_VBZ 4_CD ._. 07_CD +_NN /_NN -_: 0_CD ._. 16_CD
          nM_NN ._. Still_RB ,_, it_PRP should_MD be_VB kept_VBN in_IN mind_NN that_IN the_DT true_JJ K_NNP 
          i_NNP may_MD be_VB slightly_RB lower_JJR ._. Nonetheless_RB ,_,
          it_PRP is_VBZ clear_JJ that_IN PP_NNP 5_CD is_VBZ sensitive_JJ to_TO inhibition_NN by_IN
          okadaic_JJ acid_NN at_IN the_DT concentrations_NNS that_WDT also_RB affects_VBZ the_DT
          activity_NN of_IN PP_NNP 1_CD and_CC PP_NNP 2_CD A_DT ._. Therefore_RB ,_, when_WRB okadaic_JJ acid_NN is_VBZ
          employed_VBN to_TO treat_VB cells_NNS at_IN a_DT concentration_NN of_IN >_NN 1_CD -_: 5_CD nM_NN ,_,
          the_DT activity_NN of_IN PP_NNP 5_CD is_VBZ also_RB affected_VBN ._.
        
        
          ISIS_NNP 15534_CD promotes_VBZ nuclear_JJ localization_NN of_IN
          GR_NNP
          To_TO determine_VB whether_IN the_DT suppression_NN of_IN PP_NNP 5_CD activity_NN
          influenced_VBD the_DT subcellular_NN distribution_NN of_IN GR_NNP ,_, plasmids_NNS
          expressing_VBG a_DT GR-GFP_NNP fusion_NN protein_NN were_VBD microinjected_JJ
          into_IN cells_NNS that_WDT were_VBD previously_RB treated_VBN with_IN ISIS_NNP 15534_CD ._.
          In_IN these_DT studies_VBZ the_DT GR-GFP_NNP used_VBD was_VBD derived_VBN from_IN the_DT
          fusion_NN of_IN GFP_NNP to_TO a_DT GR_NNP mutant_JJ that_WDT retained_VBD the_DT ability_NN to_TO
          bind_NN agonist_NN ,_, translocate_NN to_TO the_DT nucleus_NN ,_, and_CC bind_NN DNA_NNP ,_,
          but_CC lacked_VBD transactivation_NN activity_NN [_NN 27_CD ]_NN ._. When_WRB plasmids_NNS
          expressing_VBG the_DT GR-GFP_NNP were_VBD injected_VBN into_IN the_DT nuclei_NN of_IN
          cells_NNS and_CC the_DT cells_NNS were_VBD grown_VBN in_IN serum-containing_JJ
          medium_NN ,_, the_DT majority_NN of_IN the_DT expressed_VBN GR-GFP_NNP localized_VBN to_TO
          the_DT nuclei_NN of_IN the_DT injected_VBN cells_NNS ,_, as_IN expected_VBN due_JJ to_TO the_DT
          presence_NN of_IN glucocorticoids_NNS in_IN the_DT serum_NN ._. Thus_RB ,_, after_IN
          microinjection_NN ,_, the_DT cells_NNS were_VBD grown_VBN in_IN medium_NN
          supplemented_JJ with_IN serum_NN for_IN 4_CD to_TO 6_CD hours_NNS and_CC then_RB serum_NN
          starved_VBN overnight_JJ to_TO cause_VB the_DT redistribution_NN of_IN GR-GFP_NNP ._.
          In_IN the_DT absence_NN of_IN serum_NN ,_, GR-GFP_NNP localized_JJ throughout_IN the_DT
          cells_NNS ,_, with_IN equal_JJ intensity_NN in_IN both_DT the_DT nucleus_NN and_CC
          cytoplasm_NN (_( Fig_NNP ._. 2_LS A_DT )_) ._. Upon_IN treatment_NN of_IN these_DT cells_NNS with_IN
          dexamethasone_NN (_( 500_CD nM_NN for_IN 30_CD minutes_NNS )_) the_DT GR-GFP_NNP
          efficiently_RB translocated_JJ to_TO the_DT nucleus_NN ._. To_TO assess_VB the_DT
          role_NN of_IN PP_NNP 5_CD in_IN the_DT intracellular_NN partitioning_VBG of_IN GR_NNP ,_,
          cells_NNS were_VBD treated_VBN with_IN ISIS_NNP 15534_CD or_CC a_DT mismatched_JJ
          control_NN (_( ISIS_NNP 15521_CD )_) at_IN a_DT concentration_NN of_IN 500_CD nM_NN ,_, which_WDT
          essentially_RB ablates_NNS PP_NNP 5_CD expression_NN in_IN A_DT 549_CD cells_NNS after_IN 24_CD
          hours_NNS [_NN 24_CD ,_, 25_CD ]_NN ._. Approximately_RB 24_CD hours_NNS after_IN antisense_NN
          treatment_NN ,_, the_DT cells_NNS were_VBD microinjected_JJ with_IN pGR_NN (_( Ala_NNP )_) -_: GFP_NNP
          and_CC subjected_VBN to_TO serum-starvation_JJ as_IN described_VBN above_IN ._. In_IN
          cells_NNS treated_VBN with_IN the_DT mismatch_NN control_NN prior_RB to_TO
          microinjection_NN ,_, GR-GFP_NNP expression_NN was_VBD indistinguishable_JJ
          from_IN that_DT in_IN untreated_JJ cells_NNS :_: GR-GFP_NNP was_VBD distributed_VBN
          evenly_RB throughout_IN the_DT cytoplasm_NN and_CC nucleus_NN (_( Figure_NN 2_CD A_DT )_) ._.
          In_IN contrast_NN ,_, following_VBG treatment_NN with_IN ISIS_NNP 15534_CD ,_, GR-GFP_NNP
          was_VBD localized_JJ in_IN the_DT nucleus_NN without_IN dexamethasone_NN
          treatment_NN ._. The_DT percentage_NN of_IN cells_NNS displaying_VBG
          predominantly_RB nuclear_JJ GR-GFP_NNP or_CC cytoplasmic_JJ GR-GFP_NNP from_IN 4_CD
          independent_JJ experiments_NNS were_VBD tabulated_JJ and_CC are_VBP presented_VBN
          in_IN Figure_NN 2_CD B_NNP ._. In_IN control_NN cells_NNS in_IN the_DT absence_NN of_IN
          dexamethasone_NN ,_, 10_CD %_NN of_IN the_DT cells_NNS showed_VBD
          nuclear_JJ >_NN cytoplasmic_JJ localization_NN of_IN GR-GFP_NNP ._. Similarly_RB ,_,
          20_CD %_NN of_IN the_DT cells_NNS treated_VBN with_IN mismatch_NN oligonucleotide_NN
          displayed_VBN greater_JJR nuclear_JJ than_IN cytoplasmic_JJ localization_NN
          of_IN GR-GFP_NNP ._. By_IN contrast_NN ,_, the_DT percentage_NN of_IN cells_NNS showing_VBG
          more_RBR nuclear_JJ than_IN cytoplasmic_JJ distribution_NN of_IN GR-GFP_NNP was_VBD
          ~_NN 93_CD %_NN ,_, ~_NN 88_CD %_NN and_CC ~_NN 98_CD %_NN in_IN cells_NNS treated_VBN with_IN either_DT
          dexamethasone_NN ,_, ISIS_NNP 15534_CD ,_, or_CC ISIS_NNP 15534_CD and_CC
          dexamethasone_NN ,_, respectively_RB ._. These_DT results_NNS suggest_VBP that_IN
          PP_NNP 5_CD plays_VBZ a_DT role_NN in_IN the_DT nucleo-cytoplasmic_JJ partitioning_VBG
          of_IN GR_NNP ._.
        
        
          Inhibition_NNP of_IN PP_NNP 5_CD expression_NN does_VBZ not_RB globally_RB
          affect_VB nuclear_JJ shuttling_VBG
          The_DT ability_NN of_IN ISIS_NNP 15534_CD treatment_NN to_TO induce_VB the_DT
          nuclear_JJ accumulation_NN of_IN GR-GFP_NNP suggests_VBZ that_IN PP_NNP 5_CD
          influences_VBZ the_DT subcellular_NN distribution_NN of_IN GR_NNP ._.
          Alternatively_RB ,_, PP_NNP 5_CD could_MD have_VB a_DT more_RBR global_JJ role_NN ,_,
          possibly_RB regulating_VBG entire_JJ nuclear_JJ transport_NN pathways_NNS ._. To_TO
          test_VB the_DT latter_NN ,_, the_DT effect_NN of_IN PP_NNP 5_CD suppression_NN on_IN the_DT
          nucleo-cytoplasmic_JJ shuttling_VBG of_IN another_DT transcription_NN
          factor_NN ,_, NFAT_NNP ,_, was_VBD investigated_VBN ._. In_IN these_DT studies_NNS ,_, a_DT
          stable_JJ GFP-NFAT_NNP expressing_VBG HeLa_NNP cell_NN line_NN was_VBD employed_VBN [_NN
          38_CD ]_NN ._. As_IN seen_VBN in_IN Figure_NN 3_CD ,_, in_IN the_DT absence_NN of_IN any_DT drug_NN ,_, the_DT
          GFP-NFAT_NNP protein_NN is_VBZ localized_VBN entirely_RB within_IN the_DT
          cytoplasm_NN ._. Upon_IN treatment_NN with_IN the_DT calcium_NN ionophore_NN
          ionomycin_NN ,_, GFP-NFAT_NNP translocates_NNS rapidly_RB to_TO the_DT nucleus_NN ._.
          The_DT fusion_NN protein_NN then_RB relocates_NNS to_TO the_DT cytoplasm_NN if_IN the_DT
          drug_NN is_VBZ washed_VBN out_IN of_IN the_DT cells_NNS for_IN 6_CD hours_NNS ._. When_WRB the_DT
          GFP-NFAT_NNP HeLa_NNP cells_NNS were_VBD treated_VBN with_IN ISIS_NNP 15534_CD ,_, the_DT
          distribution_NN of_IN GFP-NFAT_NNP was_VBD indistinguishable_JJ from_IN
          untreated_JJ cells_NNS or_CC cells_NNS treated_VBN with_IN mismatched_JJ control_NN
          oligonucleotides_NNS ._. Northern_JJ analysis_NN confirmed_VBD the_DT ability_NN
          of_IN ISIS_NNP 15534_CD to_TO suppress_VB PP_NNP 5_CD expression_NN in_IN Hela_NNP cells_NNS ._.
          Therefore_RB ,_, the_DT results_NNS indicate_VBP that_DT suppression_NN of_IN PP_NNP 5_CD
          expression_NN does_VBZ not_RB have_VB a_DT global_JJ effect_NN on_IN all_DT nuclear_JJ
          shuttling_VBG proteins_NNS ._.
        
      
      
        Discussion_NNP
        Like_IN other_JJ steroid_NN hormone_NN receptors_NNS ,_, GRs_NNP are_VBP
        phosphoproteins_NNS ,_, and_CC reversible_JJ phosphorylation_NN of_IN specific_JJ
        ser_NN /_NN thr_NN residues_NNS on_IN the_DT GR_NNP or_CC associated_VBN proteins_NNS has_VBZ been_VBN
        implicated_VBN in_IN the_DT regulation_NN of_IN 1_LS )_) hormone_NN binding_VBG to_TO the_DT
        cytoplasmic_JJ GR-complex_NNP ,_, 2_LS )_) the_DT translocation_NN of_IN the_DT GR_NNP
        between_IN the_DT cytoplasm_NN and_CC the_DT nucleus_NN ,_, 3_LS )_) the_DT binding_JJ of_IN
        ligand_NN activated_VBN GR_NNP to_TO consensus_NN GRE_NNP in_IN the_DT promoter_NN
        regions_NNS of_IN GR-responsive_NNP genes_NNS ,_, and_CC 4_LS )_) the_DT formation_NN of_IN an_DT
        active_JJ transcriptional_NN complex_JJ [_NN 1_CD ,_, 2_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ,_, 8_CD ,_, 28_CD ,_, 29_CD ,_,
        30_CD ,_, 31_CD ]_NN ._. Many_JJ of_IN the_DT kinases_NNS that_WDT catalyze_NN the_DT
        phosphorylation_NN of_IN GRs_NNP and_CC associated_VBN proteins_NNS have_VBP been_VBN
        identified_VBN ._. However_RB ,_, little_JJ is_VBZ known_VBN about_IN the_DT PPases_NNP that_WDT
        must_MD also_RB participate_VB in_IN the_DT regulation_NN of_IN GR-mediated_NNP
        signaling_VBG networks_NNS ._.
        Several_JJ recent_JJ studies_NNS indicate_VBP that_IN PP_NNP 5_CD participates_VBZ in_IN
        the_DT regulation_NN of_IN GR-induced_NNP gene_NN expression_NN ._. First_LS ,_,
        dexamethasone-induced_JJ transcription_NN is_VBZ markedly_RB enhanced_VBN
        when_WRB the_DT expression_NN of_IN PP_NNP 5_CD is_VBZ suppressed_VBN by_IN treatment_NN with_IN
        ISIS_NNP 15534_CD [_NN 25_CD ]_NN ._. Second_JJ ,_, both_DT co-immunoprecipitation_JJ
        studies_NNS and_CC studies_NNS with_IN mutant_JJ forms_NNS of_IN PP_NNP 5_CD indicate_VBP that_IN
        PP_NNP 5_CD associates_NNS with_IN the_DT GR-hsp_NNP 90_CD complex_JJ [_NN 22_CD ,_, 23_CD ]_NN ._.
        However_RB ,_, binding_JJ assays_NNS revealed_VBD that_IN the_DT suppression_NN of_IN
        PP_NNP 5_CD expression_NN has_VBZ no_DT apparent_JJ effect_NN on_IN [_NN 3_CD H_NNP ]_NN dexamethasone_NN
        binding_JJ [_NN 25_CD ]_NN ._. Therefore_RB ,_, PP_NNP 5_CD appears_VBZ to_TO act_VB as_IN a_DT
        suppressor_NN of_IN GR-induced_NNP gene_NN expression_NN via_IN a_DT mechanism_NN
        that_WDT does_VBZ not_RB alter_VB receptor_NN number_NN or_CC the_DT binding_JJ of_IN
        hormone_NN to_TO the_DT GR_NNP ._. To_TO further_VB characterize_VB the_DT relationship_NN
        between_IN PP_NNP 5_CD and_CC GR_NNP ,_, in_IN the_DT present_JJ study_NN we_PRP employed_VBN a_DT
        GR-GFP_NNP fusion_NN protein_NN to_TO track_VB the_DT movement_NN of_IN GRs_NNP in_IN A_DT 549_CD
        cells_NNS following_VBG treatment_NN with_IN hormones_NNS or_CC ISIS_NNP 15534_CD ._.
        These_DT studies_NNS revealed_VBD that_IN in_IN the_DT absence_NN of_IN
        glucocorticoids_NNS ,_, GR-GFP_NNP localized_JJ mainly_RB in_IN the_DT cytoplasm_NN ._.
        As_IN expected_VBN ,_, treatment_NN with_IN dexamethasone_NN results_NNS in_IN the_DT
        efficient_JJ translocation_NN of_IN GR-GFPs_NNP into_IN the_DT nucleus_NN ._.
        Nuclear_JJ accumulation_NN of_IN GR-GFP_NNP was_VBD also_RB observed_VBN when_WRB the_DT
        expression_NN of_IN PP_NNP 5_CD was_VBD suppressed_VBN by_IN treatment_NN with_IN ISIS_NNP
        15534_CD after_IN ~_NN 24_CD hours_NNS ._. This_DT translocation_NN of_IN GR-GFP_NNP
        occurred_VBD without_IN the_DT addition_NN of_IN glucocorticoids_NNS and_CC in_IN the_DT
        presence_NN of_IN serum_NN free_JJ media_NNS ._. Thus_RB ,_, in_IN the_DT absence_NN of_IN
        physiological_JJ concentrations_NNS of_IN PP_NNP 5_CD ,_, GRs_NNP accumulate_VBP in_IN the_DT
        nucleus_NN of_IN A_DT 549_CD cells_NNS ._. This_DT finding_VBG is_VBZ consistent_JJ with_IN data_NNS
        obtained_VBN from_IN gel-shift_JJ analysis_NN and_CC transfection_NN studies_NNS
        conducted_VBN with_IN GR-reporter_NNP plasmids_NNS ,_, where_WRB a_DT decrease_NN in_IN
        PP_NNP 5_CD levels_NNS facilitates_NNS the_DT association_NN of_IN GR_NNP with_IN DNA_NNP and_CC
        produces_VBZ an_DT increase_NN in_IN GR-transactivation_NNP [_NN 25_CD ]_NN ._. Together_RB ,_,
        these_DT studies_NNS suggest_VBP that_IN the_DT increase_NN in_IN GR-induced_NNP
        transcriptional_NN activity_NN observed_VBD when_WRB the_DT expression_NN of_IN
        PP_NNP 5_CD is_VBZ suppressed_VBN by_IN treatment_NN with_IN ISIS_NNP 15534_CD results_NNS from_IN
        the_DT nuclear_JJ accumulation_NN of_IN GR_NNP ._.
        The_DT mechanism_NN by_IN which_WDT PP_NNP 5_CD suppresses_NNS the_DT nuclear_JJ
        accumulation_NN of_IN GR_NNP is_VBZ not_RB clear_JJ ._. The_DT current_JJ data_NN is_VBZ
        consistent_JJ with_IN PP_NNP 5_CD acting_VBG to_TO suppress_VB the_DT nuclear_JJ import_NN
        of_IN GRs_NNP ._. Alternatively_RB ,_, the_DT data_NNS is_VBZ also_RB consistent_JJ with_IN PP_NNP 5_CD
        acting_VBG to_TO promote_VB the_DT nuclear_JJ export_NN of_IN the_DT GRs_NNP ._. Because_IN
        the_DT effects_NNS of_IN ISIS_NNP 15534_CD treatment_NN are_VBP not_RB readily_RB
        reversible_JJ ,_, the_DT washout_NN experiments_NNS needed_VBN to_TO distinguish_VB
        between_IN these_DT two_CD possibilities_NNS cannot_NN be_VB conducted_VBN until_IN a_DT
        specific_JJ and_CC reversible_JJ inhibitor_NN of_IN PP_NNP 5_CD is_VBZ developed_VBN ._.
        Recent_JJ studies_NNS indicate_VBP that_IN okadaic_JJ acid_NN inhibits_NNS
        nuclear_JJ transport_NN mediated_JJ by_IN import_NN receptors_NNS ,_, importin_NN β_NN
        and_CC transportin_NN ,_, suggesting_VBG that_IN an_DT okadaic_JJ acid_NN sensitive_JJ
        phosphatase_NN participates_VBZ in_IN a_DT mechanism_NN that_WDT negatively_RB
        regulates_VBZ entire_JJ nuclear_JJ transport_NN pathways_NNS [_NN 32_CD ]_NN ._. Since_IN
        PP_NNP 5_CD is_VBZ sensitive_JJ to_TO inhibition_NN by_IN okadaic_JJ acid_NN ,_, we_PRP tested_VBD
        the_DT possibility_NN that_IN PP_NNP 5_CD acted_VBD at_IN a_DT more_RBR global_JJ level_NN by_IN
        assessing_VBG the_DT effect_NN of_IN ISIS_NNP 15534_CD on_IN the_DT cellular_JJ
        distribution_NN of_IN NFAT-GFP_NNP ._. In_IN contrast_NN to_TO the_DT findings_NNS
        obtained_VBN with_IN GR-GFP_NNP ,_, the_DT suppression_NN of_IN PP_NNP 5_CD expression_NN had_VBD
        no_DT apparent_JJ effect_NN on_IN calcium_NN induced_VBD nuclear_JJ import_NN or_CC the_DT
        subsequent_JJ export_NN of_IN NFAT-GFP_NNP (_( Figure_NN 3_LS )_) ._. Therefore_RB ,_, PP_NNP 5_CD
        does_VBZ not_RB appear_VB to_TO regulate_VB entire_JJ nuclear_JJ transport_NN
        pathways_NNS ._.
      
      
        Conclusions_NNP
        These_DT studies_NNS indicate_VBP that_IN PP_NNP 5_CD participates_VBZ in_IN the_DT
        regulation_NN of_IN GR_NNP nucleocytoplasmic_JJ shuttling_VBG ,_, and_CC that_IN the_DT
        suppression_NN of_IN PP_NNP 5_CD expression_NN results_NNS in_IN the_DT nuclear_JJ
        accumulation_NN of_IN GR_NNP in_IN the_DT absence_NN of_IN hormone_NN ._. Therefore_RB ,_,
        the_DT previously_RB reported_VBN increase_NN in_IN GR-induced_NNP
        transcriptional_NN activity_NN that_WDT occurs_VBZ after_IN ISIS_NNP 15534_CD
        induced_VBN suppression_NN of_IN PP_NNP 5_CD expression_NN likely_JJ results_NNS from_IN
        the_DT nuclear_JJ accumulation_NN of_IN GR_NNP in_IN a_DT form_NN that_WDT is_VBZ capable_JJ of_IN
        binding_JJ DNA_NNP yet_RB still_RB requires_VBZ agonist_NN to_TO elicit_NN maximal_NN
        transcriptional_NN activation_NN ._. Still_RB ,_, it_PRP is_VBZ not_RB yet_RB clear_JJ if_IN
        PP_NNP 5_CD acts_NNS to_TO suppress_VB the_DT nuclear_JJ accumulation_NN or_CC to_TO
        facilitate_VB the_DT nuclear_JJ export_NN of_IN GRs_NNP ._. Thus_RB ,_, the_DT precise_JJ
        molecular_JJ mechanism_NN by_IN which_WDT PP_NNP 5_CD suppresses_NNS the_DT nuclear_JJ
        accumulation_NN of_IN GR_NNP remains_VBZ to_TO be_VB elucidated_JJ ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Reagents_NNP
          Tissue_NNP culture_NN medium_NN ,_, Lipofectin_NNP ®_NN and_CC TRIzol_NNP ®_NN were_VBD
          purchased_VBN from_IN Life_NNP Technologies_NNPS (_( Gaithersburg_NNP ,_, MD_NNP )_) ._.
          DECEprime_NNP ™_NN II_NNP DNA_NNP labeling_VBG ,_, and_CC MAXIscript_NNP ™_NN 
          in_IN vitro_NN transcription_NN kits_NNS were_VBD
          purchased_VBN from_IN Ambion_NNP Inc_NNP ._. (_( Austin_NNP ,_, TX_NNP )_) ._. [_NN α-_NN 32_CD P_NN ]_NN dATP_NN and_CC
          [_NN α-_NN 32_CD P_NN ]_NN UTP_NNP were_VBD purchased_VBN from_IN Dupont_NNP NEN_NNP (_( Boston_NNP ,_, MA_NNP )_) ._.
          Protein_NNP kinase_NN A_DT (_( 3_CD '_POS :_: 5_CD '_POS -_: cyclic_JJ AMP_NNP dependent_JJ )_) ,_,
          phosphorylase_NN b_SYM (_( EC_NNP 2_CD ._. 4_CD ._. 1_LS ._. 1_LS )_) ,_, crude_NN histone_NN (_( type_NN 2_CD AS_NNP )_)
          and_CC p-nitrophenyl_JJ phosphate_NN (_( PNPP_NNP )_) were_VBD obtained_VBN from_IN
          Sigma_NNP Chemical_NNP Company_NNP ._.
        
        
          Cell_NNP Culture_NNP
          A_DT 549_CD lung_NN carcinoma_NN cells_NNS were_VBD obtained_VBN from_IN the_DT
          American_NNP Type_NNP Tissue_NNP Collection_NNP ._. A_DT stable_JJ HeLa_NNP cell_NN line_NN
          expressing_VBG GFP-NFAT_NNP was_VBD generously_RB provided_VBN by_IN Larry_NNP
          Gerace_NNP (_( The_DT Scripps_NNP Research_NNP Institute_NNP ,_, La_NNP Jolla_NNP ,_, CA_NNP )_) ._.
          HeLa_NNP and_CC A_DT 549_CD cells_NNS were_VBD grown_VBN in_IN Dulbecco_NNP 's_POS modified_VBN
          Eagle_NNP 's_POS medium_NN containing_VBG 1_CD g_SYM of_IN glucose_NN /_NN liter_NN (_( DMEM_NNP )_) and_CC
          10_CD %_NN heat-inactivated_JJ FBS_NNP ._. All_DT cell_NN cultures_NNS were_VBD
          routinely_RB passed_VBN when_WRB 90_CD -_: 95_CD %_NN confluent_NN ._.
        
        
          Oligonucleotide_NNP Synthesis_NNP Assay_NNP for_IN Oligonucleotide_NNP
          Inhibition_NNP of_IN PP_NNP 5_CD Expression_NNP
          2_LS '_POS -_: 
          O_NNP -_: (_( 2_CD -_: methoxy_NN )_) ethylphosphothioate_NN
          oligonucleotides_NNS were_VBD synthesized_JJ and_CC purified_JJ as_IN
          previously_RB described_VBD [_NN 33_CD ]_NN ._. To_TO suppress_VB the_DT expression_NN of_IN
          PP_NNP 5_CD ,_, the_DT indicated_VBD cells_NNS were_VBD plated_JJ in_IN 60_CD mm_NN dished_JJ and_CC
          cultured_JJ in_IN DMEM_NNP containing_VBG 10_CD %_NN FCS_NNP ._. When_WRB the_DT cells_NNS were_VBD
          about_IN 70_CD %_NN confluent_NN ,_, they_PRP were_VBD treated_VBN with_IN
          oligonucleotides_NNS as_RB previously_RB described_VBD [_NN 24_CD ,_, 25_CD ]_NN ._.
          Briefly_NNP ,_, cells_NNS were_VBD washed_VBN with_IN DMEM_NNP ._. A_DT solution_NN (_( 1_CD ml_NN )_)
          of_IN DMEM_NNP containing_VBG the_DT oligonucleotides_NNS at_IN the_DT indicated_VBN
          concentration_NN and_CC 15_CD μg_NN /_NN ml_NN DOTMA_NNP /_NN DOPE_NNP (_( Lipofectin_NNP ®_NN ;_:
          GIBCO-BRL_NNP )_) was_VBD then_RB added_VBN ._. After_IN incubating_VBG the_DT cells_NNS at_IN
          37_CD °_NN C_NNP for_IN 4_CD hours_NNS ,_, the_DT cells_NNS were_VBD washed_VBN and_CC cultured_JJ in_IN
          fresh_JJ DMEM_NNP containing_VBG 10_CD %_NN FCS_NNP for_IN 17_CD hours_NNS ._. The_DT cells_NNS
          were_VBD then_RB harvested_VBN ,_, and_CC total_JJ RNA_NNP was_VBD extracted_VBN with_IN
          TRIzol_NNP Reagent_NNP (_( GIBCO-BRL_NNP )_) according_VBG to_TO the_DT methods_NNS of_IN
          the_DT manufacturer_NN ._. Total_NNP RNA_NNP (_( 20_CD μg_NN )_) was_VBD fractionated_JJ on_IN
          1_CD %_NN agarose_NN gels_NNS containing_VBG formaldehyde_NN and_CC transferred_VBN
          to_TO DURLON-UV_NNP (_( Stratagene_NNP )_) nylon_NN membranes_NNS ._. Following_VBG UV_NNP
          cross-linking_JJ ,_, the_DT filters_NNS were_VBD hybridized_JJ with_IN a_DT [_NN
          32_CD P_NN ]_NN probe_NN for_IN human_JJ PP_NNP 5_CD ._. The_DT human_JJ PP_NNP 5_CD cDNA_NN probe_NN was_VBD
          generated_VBN from_IN the_DT full_JJ length_NN coding_VBG region_NN of_IN PP_NNP 5_CD and_CC [_NN
          32_CD P_NN ]_NN labeled_VBN with_IN DECAprime_NNP ®_NN DNA_NNP Labeling_VBG Kit_NNP (_( Ambion_NNP )_)
          according_VBG to_TO the_DT manufacturer_NN 's_POS protocol_NN ._. Hybridization_NNP
          was_VBD performed_VBN in_IN the_DT presence_NN of_IN 50_CD %_NN formamide_NN at_IN 42_CD °_NN C_NNP
          for_IN 16_CD hours_NNS ._. Following_VBG hybridization_NN ,_, the_DT membrane_NN was_VBD
          subjected_VBN to_TO two_CD low_JJ stringency_NN washes_NNS (_( 2_CD ×_NN SSC_NNP )_) at_IN room_NN
          temperature_NN and_CC then_RB two_CD high_JJ stringency_NN washes_NNS (_( 0_CD ._. 1_LS ×_NN
          SSC_NNP /_NN 0_CD ._. 5_LS %_NN SDS_NNP )_) at_IN 55_CD °_NN C_NNP ._. Hybridization_NNP was_VBD visualized_JJ by_IN
          autoradiography_NN ,_, and_CC the_DT filters_NNS were_VBD then_RB stripped_VBN and_CC
          reprobed_JJ with_IN a_DT [_NN 32_CD P_NN ]_NN labeled_VBD glyceraldehyde-_NN 3_CD -_: phosphate_NN
          dehydrogenase_NN (_( GAPDH_NNP )_) cDNA_NN probe_NN to_TO confirm_VB equal_JJ
          loading_NN ._. Quantification_NNP of_IN hybridization_NN signals_NNS was_VBD
          achieved_VBN by_IN analysis_NN of_IN the_DT scanned_JJ autoradiograms_NNS using_VBG
          the_DT NIH_NNP Image_NN program_NN (_( ImagePC_NNP )_) ._.
        
        
          Preparation_NNP of_IN phosphoprotein_NN substrates_NNS
          Histone_NNP (_( type_NN 2_CD AS_NNP from_IN Sigma_NNP )_) was_VBD phosphorylated_JJ with_IN
          cAMP-dependent_JJ protein_NN kinase_NN (_( protein_NN kinase_NN A_DT )_) as_IN
          described_VBN previously_RB [_NN 34_CD ]_NN ._. Briefly_NNP ,_, 20_CD mg_NN of_IN histone_NN was_VBD
          incubated_JJ with_IN 1_CD mg_NN of_IN protein_NN kinase_NN A_DT ,_, in_IN a_DT 20_CD mM_NN
          Tris-_NNP Cl_NNP buffer_NN (_( pH_NN 7_CD ._. 4_LS )_) containing_VBG 1_CD mCi_NN [_NN 32_CD P_NN ]_NN ATP_NNP (_( 150_CD
          μM_NN ATP_NNP )_) ,_, 100_CD μM_NN cAMP_NN ,_, 5_CD mM_NN DTT_NNP ,_, and_CC 5_CD mM_NN MgCl_NNP 
          2_CD in_IN a_DT final_JJ volume_NN of_IN 4_CD ml_NN ._. The_DT
          reaction_NN was_VBD allowed_VBN to_TO continue_VB for_IN 3_CD ._. 5_CD to_TO 4_CD hrs_NNS at_IN 30_CD °_NN C_NNP
          and_CC terminated_VBN by_IN the_DT addition_NN of_IN 1_CD ._. 3_CD ml_NN of_IN 100_CD %_NN TCA_NNP ._. The_DT
          precipitated_VBD phosphohistone_NN was_VBD collected_VBN by_IN
          centrifugation_NN at_IN 3000_CD ×_NN g_SYM for_IN 5_CD min_NN ._. The_DT supernatant_NN was_VBD
          discarded_VBN ,_, and_CC the_DT pellet_NN was_VBD redissolved_JJ in_IN 4_CD ml_NN of_IN 1_CD M_NNP
          Tris-_NNP Cl_NNP (_( pH_NN 8_CD ._. 2_LS )_) ._. TCA_NNP was_VBD added_VBN to_TO precipitate_NN the_DT
          phosphohistone_NN ,_, and_CC this_DT precipitation-resuspension_JJ wash_NN
          was_VBD repeated_VBN 5_CD times_NNS ._. The_DT pellet_NN produced_VBN upon_IN the_DT sixth_JJ
          TCA_NNP precipitation_NN was_VBD washed_VBN 2_CD times_NNS with_IN 4_CD ml_NN of_IN
          ethanol_NN :_: ethyl_NN ether_NN (_( 1_CD :_: 4_CD ;_: v_NN :_: v_NN )_) and_CC then_RB 2_CD additional_JJ
          times_NNS with_IN acidified_VBN ethanol_NN :_: ethyl_NN ether_NN (_( 1_CD :_: 4_CD ;_: 0_CD ._. 1_CD N_NNP
          HCl_NNP )_) ._. The_DT washed_VBN histone_NN was_VBD allowed_VBN to_TO air_VB dry_JJ and_CC was_VBD
          then_RB resuspended_JJ in_IN 5_CD mM_NN Tris-_NNP Cl_NNP (_( pH_NN 7_CD ._. 4_LS )_) ._. This_DT procedure_NN
          yields_NNS phosphohistone_NN with_IN a_DT specific_JJ activity_NN >_NN 4_CD ._. 5_CD ×_NN
          10_CD 6_CD CPM_NNP /_NN nMole_NN incorporated_VBD phosphate_NN ._.
        
        
          Determination_NNP of_IN phosphatase_NN activity_NN
          Phosphatase_NNP activity_NN against_IN phosphohistone_NN was_VBD
          determined_VBN by_IN the_DT quantification_NN of_IN [_NN 32_CD P_NN ]_NN liberation_NN
          from_IN phosphohistone_NN as_IN described_VBN previously_RB [_NN 34_CD ]_NN ._.
          Assays_NNP ,_, 80_CD μl_NN total_JJ volume_NN ,_, containing_VBG 50_CD mM_NN Tris-_NNP HCl_NNP ,_, pH_NN
          7_CD ._. 4_CD ,_, 0_CD ._. 5_CD mM_NN DTT_NNP ,_, 1_CD mM_NN EDTA_NNP ,_, 100_CD μM_NN oleic_JJ acid_NN (_( assay_NN
          buffer_NN )_) and_CC [_NN 32_CD P_NN ]_NN phosphoprotein_NN (_( 1_CD -_: 2_CD μM_NN PO_NNP 
          4_LS )_) ,_, were_VBD conducted_VBN at_IN 37_CD °_NN C_NNP as_IN
          described_VBN previously_RB [_NN 34_CD ]_NN using_VBG PP_NNP 5_CD purified_JJ from_IN bovine_JJ
          brain_NN ._. The_DT serine_NN /_NN threonine_NN protein_NN phosphatase_NN type_NN 5_CD
          (_( PP_NNP 5_LS )_) was_VBD purified_JJ from_IN bovine_JJ brain_NN according_VBG to_TO the_DT
          following_JJ procedure_NN :_: a_DT bovine_JJ brain_NN was_VBD homogenized_JJ in_IN ~_NN
          3_CD volumes_NNS of_IN buffer_NN A_DT (_( 50_CD mM_NN HEPES_NNP pH_NN 7_CD ._. 5_CD 4_CD °_NN C_NNP ,_, 1_CD mM_NN EDTA_NNP ,_,
          10_CD mM_NN PMSF_NNP and_CC 0_CD ._. 1_CD %_NN 2_CD -_: mercaptoethanol_NN )_) and_CC subjected_VBN to_TO
          centrifugation_NN at_IN 15_CD ,_, 000_CD g_SYM for_IN 40_CD min_NN ._. followed_VBN by_IN a_DT
          45_CD %_NN -_: 60_CD %_NN ammonium_NN sulfate_NN fractionation_NN of_IN the_DT
          supernatant_NN ._. The_DT pellets_NNS from_IN the_DT ammonium_NN sulfate_NN
          fractionation_NN were_VBD resuspended_JJ in_IN 60_CD ml_NN of_IN buffer_NN B_NNP (_( 20_CD
          mM_NN HEPES_NNP pH_NN 8_CD ._. 5_CD 4_CD °_NN C_NNP ,_, 1_CD mM_NN EDTA_NNP ,_, and_CC 0_CD ._. 1_CD %_NN
          2_CD -_: mercaptoethanol_NN )_) ,_, desalted_JJ on_IN a_DT G-_NNP 25_CD sephadex_NN column_NN
          equilibrated_JJ with_IN buffer_NN B_NNP ,_, then_RB subjected_VBN to_TO sequential_NN
          chromatography_NN on_IN a_DT 5_CD ml_NN HiTrap_NNP Heparin_NNP column_NN
          (_( Pharmacia_NNP )_) ,_, a_DT 5_CD ml_NN HiTrap_NNP Q_NNP column_NN (_( Pharmacia_NNP )_) and_CC a_DT
          HiTrap_NNP SP_NNP column_NN (_( Pharmacia_NNP )_) respectively_RB ._. The_DT eluate_NN
          from_IN the_DT SP_NNP column_NN was_VBD then_RB diluted_VBN 5_CD -_: fold_VB with_IN buffer_NN C_NNP
          (_( 20_CD mM_NN tris_NNS pH_NN 8_CD ._. 5_CD ,_, 1_CD mM_NN EDTA_NNP and_CC 0_CD ._. 1_CD %_NN 2_CD -_: mercaptoethanol_NN )_)
          and_CC subjected_VBN to_TO anion-exchange_JJ chromatography_NN on_IN a_DT
          BioScale_NNP Q_NNP column_NN (_( 2_CD ml_NN from_IN BioRad_NNP )_) ._. All_DT steps_NNS in_IN the_DT
          purification_NN procedure_NN were_VBD performed_VBN at_IN 4_CD °_NN C_NNP except_IN for_IN
          the_DT last_JJ step_NN which_WDT was_VBD performed_VBN at_IN 23_CD °_NN C_NNP ._. PP_NNP 5_CD activity_NN
          was_VBD followed_VBN during_IN the_DT purification_NN by_IN assaying_VBG for_IN
          trypsin-stimulated_JJ phosphohydrolase_NN activity_NN at_IN 37_CD °_NN C_NNP vs_NNS ._.
          p-nitrophenyl_JJ phosphate_NN in_IN 200_CD μl_NN reactions_NNS containing_VBG :_:
          25_CD mM_NN tris_NNS pH_NN 8_CD ._. 3_CD ,_, 25_CD mM_NN MgCl_NNP 
          2_CD ,_, 1_CD mM_NN DTT_NNP and_CC 10_CD mM_NN p-nitrophenyl_JJ
          phosphate_NN ._.
          Dephosphorylation_NNP reactions_NNS were_VBD routinely_RB conducted_VBN
          for_IN 10_CD minutes_NNS and_CC initiated_VBN with_IN the_DT addition_NN of_IN
          substrate_NN ._. The_DT dephosphorylation_NN of_IN substrate_NN was_VBD kept_VBN to_TO
          less_JJR than_IN 10_CD %_NN of_IN the_DT total_JJ phosphorylated_JJ substrate_NN ,_, and_CC
          the_DT reaction_NN was_VBD linear_JJ with_IN respect_NN to_TO enzyme_NN
          concentration_NN and_CC time_NN ._. [_NN 32_CD P_NN ]_NN phosphate_NN liberated_VBD by_IN the_DT
          enzymes_NNS was_VBD extracted_VBN as_IN a_DT phosphomolybdate_NN complex_JJ and_CC
          measured_VBN according_VBG to_TO the_DT methods_NNS of_IN Killilea_NNP et_CC al_NN ._. [_NN
          35_CD ]_NN ._. Inhibition_NNP of_IN phosphatase_NN activity_NN by_IN okadaic_JJ acid_NN
          was_VBD determined_VBN by_IN adding_VBG the_DT inhibitors_NNS to_TO the_DT enzyme_NN
          mixture_NN 10_CD minutes_NNS prior_RB to_TO initiating_VBG the_DT reaction_NN with_IN
          the_DT addition_NN of_IN substrate_NN ._.
        
        
          GR-GFP_NNP expression_NN vectors_NNS
          A_DT mutant_JJ rat_NN glucocorticoid_NN receptor_NN that_WDT retained_JJ
          hormone_NN binding_JJ ,_, nuclear_JJ translocation_NN activity_NN ,_, and_CC
          specific_JJ DNA_NNP binding_JJ activity_NN ,_, but_CC was_VBD incapable_JJ of_IN
          transactivation_NN was_VBD fused_JJ to_TO a_DT S_NNP 65_CD T_NN mutant_JJ of_IN green_JJ
          fluorescent_NN protein_NN to_TO create_VB pGR_NN (_( Ala_NNP )_) -_: GFP_NNP ._. GR_NNP (_( Ala_NNP )_) -_: GFP_NNP
          expression_NN is_VBZ driven_VBN by_IN the_DT CMV_NNP immediate_JJ early_JJ promoter_NN
          and_CC enhancer_NN ._. All_DT manipulations_NNS were_VBD performed_VBN as_IN
          described_VBN ,_, and_CC all_DT constructs_NNS were_VBD confirmed_VBN by_IN
          sequencing_VBG [_NN 36_CD ]_NN ._. Protein-free_NNP plasmid_NN DNA_NNP was_VBD purified_JJ
          using_VBG Qiagen_NNP maxiprep_NN columns_NNS (_( San_NNP Diego_NNP ,_, CA_NNP )_) and_CC
          contained_VBD predominantly_RB supercoiled_JJ plasmid_NN with_IN no_DT
          contaminating_VBG RNA_NNP or_CC low_JJ molecular_JJ weight_NN
          contaminants_NNS ._.
        
        
          GFP-GR_NNP translocation_NN
          Cells_NNP were_VBD plated_JJ on_IN etched_JJ coverslips_NNS and_CC grown_VBN until_IN
          the_DT cultures_NNS were_VBD ~_NN 70_CD %_NN confluent_NN ._. The_DT cells_NNS were_VBD then_RB
          either_CC treated_VBN with_IN oligonucleotides_NNS as_IN described_VBN above_IN
          or_CC left_VBD untreated_JJ ._. Eighteen_CD hours_NNS later_RB ,_, purified_JJ
          protein-free_JJ pGR_NN (_( Ala_NNP )_) -_: GFP_NNP suspended_VBD in_IN phosphate-buffered_JJ
          saline_NN (_( 0_CD ._. 25_CD mg_NN /_NN ml_NN )_) was_VBD microinjected_JJ into_IN the_DT nuclei_NN of_IN
          the_DT cells_NNS [_NN 37_CD ]_NN ._. Typically_RB ,_, 150_CD -_: 200_CD cells_NNS were_VBD injected_VBN
          for_IN each_DT condition_NN ._. After_IN microinjection_NN the_DT cells_NNS were_VBD
          incubated_JJ in_IN medium_NN containing_VBG 10_CD %_NN FBS_NNP for_IN 6_CD hours_NNS at_IN
          37_CD °_NN C_NNP ._. The_DT cells_NNS were_VBD then_RB washed_VBN several_JJ times_NNS with_IN
          serum-free_JJ media_NNS and_CC placed_VBN in_IN serum_NN deficient_NN media_NNS for_IN
          14_CD hours_NNS to_TO prevent_VB GFP-GR_NNP translocation_NN to_TO the_DT nucleus_NN ,_,
          prior_RB to_TO treatment_NN with_IN 500_CD nM_NN dexamethasone_NN (_( 30_CD min_NN ._. )_) or_CC
          with_IN vehicle_NN alone_RB ._. The_DT cells_NNS were_VBD washed_VBN 3_CD times_NNS with_IN
          PBS_NNP ,_, fixed_VBN by_IN incubation_NN in_IN PBS_NNP supplemented_JJ with_IN 4_CD %_NN
          paraformaldehyde_NN for_IN 10_CD min_NN and_CC washed_VBN again_RB 3_CD times_NNS with_IN
          PBS_NNP before_IN mounting_VBG on_IN slides_NNS with_IN DABCO_NNP /_NN DAPI_NNP mounting_VBG
          solution_NN ._. GR-GFP_NNP expression_NN and_CC localization_NN were_VBD
          monitored_VBN by_IN fluorescence_NN microscopy_NN ._. Nuclei_NNP were_VBD
          localized_VBN by_IN DAPI_NNP staining_VBG ._. Images_NNP were_VBD captured_VBN with_IN an_DT
          Optronics_NNP cooled_VBD CCD_NNP camera_NN and_CC imported_VBN into_IN Adobe_NNP
          Photoshop_NNP ._. The_DT experiments_NNS were_VBD repeated_VBN 4_CD times_NNS (_( 6_CD for_IN
          control_NN )_) ._. One-way_NNP ANOVA_NNP was_VBD performed_VBN to_TO determine_VB
          statistical_JJ significance_NN of_IN the_DT results_NNS using_VBG Instat_NNP 2_CD ._. 03_CD
          (_( GraphPad_NNP Software_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP )_) ._.
        
        
          GFP-NFAT_NNP nuclear_JJ shuttling_VBG assay_NN
          Stably-transfected_NNP HeLa_NNP cells_NNS expressing_VBG GFP-NFAT_NNP [_NN
          38_CD ]_NN were_VBD grown_VBN on_IN glass_NN coverslips_NNS to_TO approximately_RB 30_CD %_NN
          confluency_NN and_CC either_CC left_VBD untreated_JJ or_CC treated_VBN with_IN ,_,
          ISIS_NNP 15534_CD ,_, or_CC ISIS_NNP 15521_CD (_( a_DT mismatched_JJ oligonucleotide_NN
          control_NN for_IN ISIS_NNP 15534_CD )_) in_IN the_DT absence_NN of_IN serum_NN as_IN
          described_VBN above_IN ._. Four_CD hours_NNS later_RB ,_, FBS_NNP was_VBD added_VBN to_TO 10_CD %_NN
          and_CC the_DT cells_NNS were_VBD grown_VBN for_IN an_DT additional_JJ 24_CD hours_NNS ._. The_DT
          cells_NNS were_VBD then_RB treated_VBN with_IN 1_CD μM_NN ionomycin_NN for_IN 30_CD
          minutes_NNS ,_, after_IN which_WDT time_NN they_PRP were_VBD either_CC fixed_VBN
          immediately_RB or_CC washed_VBN extensively_RB with_IN PBS_NNP and_CC incubated_JJ
          for_IN 6_CD hours_NNS in_IN medium_NN lacking_VBG the_DT drug_NN (_( "_'' washout_NN "_'' )_) ._.
          Control_NN cells_NNS were_VBD not_RB incubated_JJ with_IN ionomycin_NN ._. GFP-NFAT_NNP
          localization_NN was_VBD monitored_VBN by_IN fluorescence_NN microscopy_NN ,_,
          and_CC images_NNS were_VBD captured_VBN with_IN an_DT Optronics_NNP cooled_VBD CCD_NNP
          camera_NN and_CC imported_VBN into_IN Adobe_NNP Photoshop_NNP ._.
        
      
    
  
